Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06724653

Acronym

HFrecEF

Enrollment

150

Registered

2024-12-09

Start date

2025-03-06

Completion date

2027-11-26

Last updated

2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ejection Fraction, Heart Failure, Recovery of Function

Keywords

heart failure with recovered ejection fraction, Tapering

Brief summary

Study start date is on Nov 27th 2024. A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.

Detailed description

Patients described above randomly assigned to drug tapering group and drug maintaining group. Drug tapering group is 2 groups, which one is RAS blocker tapering group and others is beta blocker tapering group. Drug tapering group is monitored ejection fraction, LV dimension and LV GLS by 1-3 month.

Interventions

DRUGRAS blocker tapering group

RAS blocker tapering out

DRUGBeta blocker tapering out

Beta blocker tapering out group

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Intervention model description

randomly assignment to 3 groups ( drug tapering\_RAS blocker, beta blocker, drug maintaining)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* initial echocardiogram ejection fraction less than 40% * follow up echocardiogram ejection fraction over 50% and LVEDD index normal range * NTprobnp criteria 1. eGFR ≥60 ; less 440 2. eGFR 45-59: less 980 3. eGFR 30-44; less 1220 4. eGFR \< 30 : less 5300 5. in HD; no criteria for NTproBNP * on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor)

Exclusion criteria

1. under age 18 year 2. uncontrolled BP ( over 150/90) 3. coronary revascularization within 6 months 4. significant valve disease 5. arrhythmia requiring rate control 6. CKD with albuminuria ( over 30mg/g) 7. Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Heart failure relapse	From enrollment to the end of treatment at 18 months	LVEF 10% drop, EF less than 50 %, LVIDd/BSA 10% increase, over 33mm/m\^2

Countries

South Korea

Contacts

CONTACTYujin Yang

wjsdudtns9@gmail.com821043311245

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026